Washington Institute for Coagulation | Seattle, WA

Research site

(Unclaimed)

Location

701 Pike Street Suite 1900, Seattle, Washington, United States of America

Site insights

Top conditions

Top treatments

PF-06741086

Emicizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 6 total trials

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

The purpose of the study is to evaluate the safety, tolerability and time-course profile of FVIII activity after dosing with SB-525 (PF-07055480)

Active, not recruiting

Hemophilia A

Biological: SB-525 (PF-07055480)

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6)

This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab i...

Active, not recruiting

Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

Hemophilia A

Drug: Emicizumab

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profi...

Active, not recruiting

Hemophilia B

Biological: Factor IX (FIX)

Genetic: AAV5-hFIXco-Padua

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or...

Enrolling

Hemophilia B

Hemophilia A

Diagnostic Test: Testing of hepatic AAV Vector integration

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to...

Active, not recruiting

Hemophilia B

Hemophilia A

Drug: PF-06741086

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (AFFINE)

C3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec...

Active, not recruiting

Hemophilia A

Biological: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms